Zymeworks Inc.

Zymeworks is a global biotechnology company focused on discovering, developing, and commercializing novel biotherapeutics for difficult-to-treat diseases, with a primary focus on oncology, inflammation, and autoimmune disorders. The company’s pipeline includes antibody-drug conjugates (ADCs) and multispecific antibody therapeutics (MSATs) engineered using proprietary technology platforms such as Azymetric, EFECT, and ProTECT. Its lead asset, zanidatamab (marketed as Ziihera), has received regulatory approval for treating HER2-positive biliary tract cancer, alongside earlier-stage candidates including pasritamig, ZW191, ZW251, ZW220, ZW209, and ZW1528. Rather than commercializing all programs independently, the company licenses assets and enters into strategic risk-sharing collaborations with biopharmaceutical partners, including Jazz Pharmaceuticals, BeOne Medicines, and Johnson & Johnson.

The company operates globally through multinational clinical development programs and licensing agreements spanning major international markets. Its clinical trials and commercialization agreements cover North America, Europe, the Asia-Pacific region, and China. Regulatory authorizations and clinical development activities have been established in the United States, Europe, Canada, Japan, and China. Information regarding specific corporate headquarters facilities or employee headcount is not specified in the provided text.

Summary of the business section of Zymeworks's latest annual report, written by StockData.

“Actually paid” adjusts reported pay for changes in the value of equity awards. Shareholder return assumes $100 invested at the start of the measurement period, as disclosed by the company.

“As of December 31, 2025, we had 264 full-time employees, 204 of whom were primarily engaged in research and development activities and 60 of whom hold an M.D.”